LGND


Ligand and GlaxoSmithKline Announce Expansion of Agreement

This article was originally published on TipRanks.com Ligand Pharmaceuticals’ (LGND) subsidiary Icagen and GlaxoSmithKline (GSK) have announced plans to expand their collaboration and license …

Ligand Closes $438M Pfenex Deal; Street Sees 84% Upside

Ligand Pharmaceuticals announced that it has completed the acquisition of Pfenex Inc. for $437.

Pfenex Pops 59% On Ligand $513M Buy-Out Deal; Analyst Sees 93% Upside

Ligand Pharmaceuticals has entered into an agreement to buy Pfenex in an all-stock deal for a total consideration of $513 million. As part …

Ligand Pharmaceuticals Inc. (LGND) Enters into Commercial License and Supply Agreement with Sanofi SA (SNY) for Captisol-enabled SAR-125844

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces it has entered into a global license and supply agreement with Sanofi SA (ADR) (NYSE:SNY) to utilize Captisol in …

Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Receives CHMP Positive Opinion for Revolade

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion …

Company Update (NASDAQ:LGND): FDA Approves Ligand Pharmaceuticals Inc.’s Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta® (eltrombopag), a Novartis product, …

Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from …

Company Update (NASDAQ:LGND): Ligand PHarmaceuticals Inc. Partner Viking Therapeutics Inc Announces Closing of Initial Public Offering

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) partner Viking Therapeutics Inc (NASDAQ:VKTX) announced that it had closed its initial public offering (the “Viking IPO”) of 3,000,000 …

Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc Partner Viking Therapeutics Inc Announces Pricing of Initial Public Offering

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) partner Viking Therapeutics Inc (NASDAQ:VKTX) announced that it has priced its initial public offering of 3,000,000 shares of its …

Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Names Melanie J. Herman Interim Chief Financial Officer

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the appointment of Melanie J.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts